Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC008055 | Panoply™ Human KDM6B Knockdown Stable Cell Line | Inquiry |
| CSC-SC008055 | Panoply™ Human KDM6B Over-expressing Stable Cell Line | Inquiry |
| CLKO-1033 | KDM6B KO Cell Lysate-HEK293T | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD08512Z | Human KDM6B adenoviral particles | Inquiry |
| LV16123L | human KDM6B (NM_001080424) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH324279 | shRNA set against Human KDM6B (NM_001080424.1) | Inquiry |
| SHH324283 | shRNA set against Mouse KDM6B (NM_001017426.1) | Inquiry |
| SHH324287 | shRNA set against Rat KDM6B (NM_001108829.1) | Inquiry |
| SHW009171 | shRNA set against Danio rerio KDM6BB (NM_001030178) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDFH009747 | Human KDM6B cDNA Clone(NM_001080424.1) | Inquiry |
| CDFR008397 | Rat Kdm6b cDNA Clone(NM_001108829.1) | Inquiry |
| MiUTR1H-05070 | KDM6B miRNA 3'UTR clone | Inquiry |
| MiUTR1M-06187 | KDM6B miRNA 3'UTR clone | Inquiry |
| MiUTR1R-02736 | KDM6B miRNA 3'UTR clone | Inquiry |
| SKO0556 | KDM6B Validated sgRNA vector | Inquiry |
| CDCB170646 | Danio rerio KDM6BB ORF Clone (NM_001030178) | Inquiry |
| CDCB191858 | Rabbit KDM6B ORF clone (XM_008270772.1) | Inquiry |
| CDCL122393 | Human Jmjd3 ORF clone (NM_001017426.1) | Inquiry |
| CDCL123661 | Human KDM6B ORF clone (NM_001080424.1) | Inquiry |
| CDCR375452 | Rat Kdm6b ORF Clone(NM_001108829.1) | Inquiry |
Recent Research
KDM6B, also known as Jmjd3, has been identified as an H3K27 demethylase that catalyzes the demethylation of H3K27me2/3. KDM6B is an inducible demethylase acting on H3K27me2,3, which represents an inhibitory epigenetic histone marker. Interestingly, expression of KDM6B can be activated by transcription factors that transduce signals triggered by inflammatory mediators and a variety of stress conditions. Induction of KDM6B is an important host defense response against environmental attack and cellular stress, as KDM6B stimulates a wide range of genes, including pro-inflammatory agents and factors that prevent cell proliferation. In addition, KDM6B regulates inflammatory responses through STAT6 (Signal transducers and activators of transcription), such as M2 polarization, and directs the typing of CD4+ T cells by T-bet factor. The p53 and INK4 box genes are major targets for the regulation of cellular senescence involved in KDM6B-induced senescence. KDM6B also prevents cancer formation by oncogene-induced senescence (OIS), as RAS and p53 signaling stimulate KDM6B function. Accordingly, KDM6B can produce developmental responses as well as induce cellular senescence. Therefore, KDM6B is an epigenetic regulator that is located in the relationship between inflammation and cellular senescence.
Recent studies in the molecular biology of KDM6B have shown that the expression of KDM6B can be induced by many inflammatory mediators as well as stress inducers such as metabolism, hypoxia and carcinogenic stress. Subsequently, KDM6B enhances transcription of inflammatory genes through a number of signaling pathways mediated by, for example, NF-κB, STAT, SMAD and T-bet transcription factors. KDM6B triggers transcription of the target gene by demethylating the inhibitory H3K27me3 epigenetic marker or mediating the interaction between chromatin modifiers, thereby activating gene transcription in a manner independent of demethylase.
Figure 1. Schematic diagram depicting the regulatory network associated with KDM6B.
KDM6B also plays a key role in osteogenic differentiation by removing H3K27me3 from the promoter of osteogenic genes in human bone marrow stromal cells (BMSCs). A recent study showed that KDM6B plays a key role in epigenetic regulation of odontogenic differentiation of human dental pulp stem cells (DPSCs). In DPSCs, KDM6B knockdown studies resulted in decreased alkaline phosphatase activity and alizarin red staining, and decreased expression of marker genes, including osterix (OSX), osteocalcin (OCN) and osteopontin (OPN). KDM6B is involved in the control of calcium-induced differentiation, regulates osteoblast differentiation, promotes neuronal survival and differentiation, odontogenic differentiation of DPSC, and osteogenic differentiation of human BMSCs. Calcium-induced differentiation has been reported to result in increased binding of KDM6B and erasure of inhibitory markers such as H3K27me3. BMP4/7-mediated SMAD1/4 activation has been shown to induce KDM6B expression and trigger the osteogenic pathway. Mechanically, KDM6B is recruited to the bone morphogenetic protein 2 (BMP2) and HOX (homology gene) promoters and activates expression of genes associated with odontogenic differentiation. KDM6B removes the epigenetic marker H3K27me3 from the promoter of the osteogenic gene to promote osteogenic commitment. In addition, a recent study demonstrated the promotion of KDM6B to odontogenic differentiation.
KDM6B is known to play a key role in development, cancer, neurodegenerative diseases, aging and inflammatory diseases. Additionally, it has been reported that KDM6B can promote chondrocyte proliferation and hypertrophy during endochondral bone formation in KDM6B−/− mice. Recent studies have shown that KDM6B is critical for cartilage development and homeostasis, and that abnormal changes in KDM6B expression in OA cartilage may provide a promising therapeutic target for OA therapy.
References: